{"preliminary_commentary":{"by_channel":{"x_thread":6,"podcast":3,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT02746952\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["UCART19"]],"indication":"relapsed/refractory CD19-positive B-cell acute lymphoblastic leukemia","name":"CALM","nct_id":"NCT02746952","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=calm-nct02746952. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"CALM","arms":[{"description":null,"label":"UCART19","type":"EXPERIMENTAL"}],"collaborators":["ADIR, a Servier Group company"],"completion_date":{"date":"2020-07-28","type":"ACTUAL"},"conditions":["B-cell Acute Lymphoblastic Leukemia"],"enrollment":{"count":25,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"UCART19","otherNames":["S68587"],"type":"BIOLOGICAL"}],"last_update":"2021-10-01","lead_sponsor":"Institut de Recherches Internationales Servier","official_title":"Phase I, Open Label, Dose-escalation Study Followed by a Safety Expansion Part to Evaluate the Safety, Expansion and Persistence of a Single Dose of UCART19 (Allogeneic Engineered T-cells Expressing Anti-CD19 Chimeric Antigen Receptor), Administered Intravenously in Patients With Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukaemia (B-ALL)","overall_status":"COMPLETED","phases":["PHASE1"],"primary_completion_date":{"date":"2020-07-28","type":"ACTUAL"},"primary_outcomes":[{"measure":"Dose escalation part: Dose Limiting Toxicities (DLTs) occurence. Dose expansion part: AE throughout the study.","timeFrame":"Dose Escalation: Up to day 28 post first UCART19 infusion. Dose Expansion: From inclusion to Month 12"}],"references":[{"citation":"Benjamin R, Graham C, Yallop D, Jozwik A, Mirci-Danicar OC, Lucchini G, Pinner D, Jain N, Kantarjian H, Boissel N, Maus MV, Frigault MJ, Baruchel A, Mohty M, Gianella-Borradori A, Binlich F, Balandraud S, Vitry F, Thomas E, Philippe A, Fouliard S, Dupouy S, Marchiq I, Almena-Carrasco M, Ferry N, Arnould S, Konto C, Veys P, Qasim W; UCART19 Group. Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies. Lancet. 2020 Dec 12;396(10266):1885-1894. doi: 10.1016/S0140-6736(20)32334-5.","pmid":"33308471","type":"RESULT"},{"citation":"Li YR, Zhu Y, Fang Y, Lyu Z, Yang L. Emerging trends in clinical allogeneic CAR cell therapy. Med. 2025 Aug 8;6(8):100677. doi: 10.1016/j.medj.2025.100677. Epub 2025 May 13.","pmid":"40367950","type":"DERIVED"},{"citation":"Benjamin R, Jain N, Maus MV, Boissel N, Graham C, Jozwik A, Yallop D, Konopleva M, Frigault MJ, Teshima T, Kato K, Boucaud F, Balandraud S, Gianella-Borradori A, Binlich F, Marchiq I, Dupouy S, Almena-Carrasco M, Pannaux M, Fouliard S, Brissot E, Mohty M; CALM Study Group. UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial. Lancet Haematol. 2022 Nov;9(11):e833-e843. doi: 10.1016/S2352-3026(22)00245-9. Epub 2022 Oct 10.","pmid":"36228643","type":"DERIVED"}],"start_date":{"date":"2016-08-01","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Dose Escalation Study of UCART19 in Adult Patients With Relapsed / Refractory B-cell Acute Lymphoblastic Leukaemia","url":"https://clinicaltrials.gov/study/NCT02746952"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/calm-nct02746952"}